Integrin β4 in Breast Cancer: A Focused Review  

作　　者：Zoya Salahuddin Shuhan Ying Emily Xie Aizhang Xu Xiaojing Ma Zoya Salahuddin;Shuhan Ying;Emily Xie;Aizhang Xu;Xiaojing Ma(Weill Cornell Medicine-Qatar, Doha, Qatar;Syosset High School, Syosset, New York;Department of Mathematics, University of California, San Diego, USA;Department of Microbiology and Immunology, Meyer Cancer Center, Weill Cornell Medicine, New York, USA)

机构地区：[1]Weill Cornell Medicine-Qatar, Doha, Qatar [2]Syosset High School, Syosset, New York [3]Department of Mathematics, University of California, San Diego, USA [4]Department of Microbiology and Immunology, Meyer Cancer Center, Weill Cornell Medicine, New York, USA

出　　处：《Journal of Biosciences and Medicines》2024年第11期255-272,共18页生物科学与医学（英文）

摘　　要：Integrin β4 (ITGB4) is emerging as a pivotal player in breast cancer progression, particularly in aggressive and invasive subtypes such as triple-negative breast cancer (TNBC). This review broadly summarizes current research on ITGB4’s involvement in breast cancer, focusing on its role in metastasis, metabolic reprogramming, drug resistance, and immunoregulation that collectively influence tumor behavior with implications for the development of innovative and more efficacious therapeutic modalities.Integrin β4 (ITGB4) is emerging as a pivotal player in breast cancer progression, particularly in aggressive and invasive subtypes such as triple-negative breast cancer (TNBC). This review broadly summarizes current research on ITGB4’s involvement in breast cancer, focusing on its role in metastasis, metabolic reprogramming, drug resistance, and immunoregulation that collectively influence tumor behavior with implications for the development of innovative and more efficacious therapeutic modalities.

关 键 词：INTEGRINS ITGB4 Prognosis EMT ANGIOGENESIS Drug Resistance Cancer Therapy 

分 类 号：R73[医药卫生—肿瘤]